A study to evaluate safety, interaction with the body (pharmacokinetics), and clinical activity of combination of RO6870810 and venetoclax, with or without rituximab, in participants with cancer of the white blood cells (lymphoma)
| ISRCTN | ISRCTN17568633 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17568633 |
| EudraCT/CTIS number | 2017-000357-39 |
| ClinicalTrials.gov number | NCT03255096 |
| Secondary identifying numbers | NP39461 |
- Submission date
- 12/11/2020
- Registration date
- 01/12/2020
- Last edited
- 16/03/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English Summary
Background and study aims:
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are "blood cancers" in the lymph nodes. They develop more frequently in older adults and in immunocompromised individuals. B-cell lymphomas include both Hodgkin's lymphomas and most non-Hodgkin lymphomas.
This open-label, two-part study is designed to evaluate the safety, tolerability and clinical activity of RO6870810/venetoclax, with or without rituximab, in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and/or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH). Part 1 is a dose-escalation of RO6870810/venetoclax with or without rituximab. Part 2 will evaluate the preliminary clinical activity at the recommended triple combination doses and explore biomarker endpoints. If the triple regimen is not tolerated, the dual combination of RO6870810/venetoclax will be evaluated in Part 2
Who can participate?
Participants with relapsed/refractory DLBCL and/or high-Grade B-Cell lymphoma and/or high-grade B-Cell Lymphoma with MYC and/or BCL2 and/or BCL6
What does the study involve?
In Part 1, a dose-escalation scheme will be employed to evaluate the combination of RO6870810/venetoclax. Subsequently, the recommended dose (RD) of RO6870810/venetoclax co-administered with rituximab will be established for further evaluation in Part 2. If this triple regimen is not well tolerated, the RD of the dual combination of RO6870810/venetoclax will be evaluated in Part 2. Participants will be enrolled in a cohort in a staggered manner, with a minimum of 7 days between the first-dosed and subsequent participants in a given cohort. Up to 6 cohorts with a minimum of 3 participants are planned for the double dose escalation in Part 1. Participants may be enrolled in up to 3 additional cohorts (termed Cohorts 4a, 5a and 6a) to receive RO6870810/venetoclax co-administered with rituximab.
The dose-expansion part will open once the RDs of RO6870810/venetoclax co-administered with rituximab have been established in Part 1. Part 2 will consist of two groups: Group 1 N=40 DLBCL participants. Group 2 N=40 DE-DLBCL (expression MYC 40%, BCL2 > 50%) and/or HGBL-DH/TH participants. Participants will receive treatments until they experience unacceptable toxicities or until documented disease progression. If, in the opinion of the Investigator, a patient is experiencing clinical benefit despite disease progression, the patient may continue study treatments following discussion with the sponsor.
Note that due to the early termination of this study, Part 2 was not conducted.
What are the possible benefits and risks of participating?
Patients with DLBCL (including DE-DLBCL) and HGBL-DH/TH who have relapsed or are refractory to first-line regimen and are not eligible for ASCT represent a group with a significant need for novel therapies to be developed. RO6870810, venetoclax, and rituximab have potential for independent anti-tumor effects, and other data suggest potential for synergistic benefit in relapsed or refractory DLBCL and/or HGBL-DH/TH participants.
Based on the safety profiles for RO6870810, venetoclax, and rituximab in B-cell NHL patients, there is potential for some overlapping toxicities. Combined administration of RO6870810 with venetoclax may enhance some of the toxicities associated with each compound, including neutropenia and associated complications, anemia, thrombocytopenia, gastrointestinal (GI) disorders (nausea, diarrhea, vomiting), and fatigue. TLS is a known risk when initiating treatment with venetoclax and to a lower extent with rituximab.
Considering the anticipated activity of the combination, the known safety profile of therapeutic agents and effective measures in place to mitigate and manage toxicities, it is believed that the overall benefit/risk assessment for this combination is favorable and justifies its exploration in relapsed and refractory DLBCL (including DE-DLBCL) and HGBL-DH/TH disease.
Where is the study run from?
Genentech Ltd. (USA)
When is the study starting and how long is it expected to run for?
December 2016 to July 2019
Who is funding the study?
F. Hoffmann-La Roche Ltd
Who is the main contact?
global-roche-genentech-trials@gene.com
Contact information
Public
1 DNA Way
South San Francisco
94080
United States of America
| Phone | +1 888-662-6728 |
|---|---|
| global-roche-genentech-trials@gene.com |
Study information
| Study design | Interventional non-randomized trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet. |
| Scientific title | Open-Label, dose escalation/expansion phase ib study to evaluate the safety, pharmacokinetics, and clinical activity of the combination of RO6870810 and venetoclax, with or without rituximab, in patients with relapsed/refractory diffuse large B-Cell lymphoma and/or high–grade B cell lymphoma with MYC and/or BCL2 and/or BCL6 gene rearrangements |
| Study hypothesis | To evaluate the safety, tolerability and clinical activity of RO6870810 in combination with venetoclax and when co-administered with rituximab in participants with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and/or high-grade B-cell lymphoma with myelocytomatosis oncogene (MYC) and/or B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) gene rearrangements (HGBL-DH/TH). |
| Ethics approval(s) | Approved 15/06/2017, Western Institutional Review Board (1019 39th Avenue SE, Suite 120, Pullayup, WA, 98374-2115, USA; +1 3602522500; no email address provided), ref: 20171189 |
| Condition | B-Cell Lymphoma |
| Intervention | Treatment assignment for both doublet and triplet dosing in Part 1 will be via slot allocation by the Sponsor. Participants will be assigned sequentially to treatment. When Cohorts 4 and 5 are both eligible for recruitment, open slots of Cohort 4 will be filled first. A screening request and approval process will ensure that the correct dose is selected and assigned for participant dosing. Experimental: Dose Escalation Phase (Part 1) Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death. Drug: RO6870810 RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles. Drug: Venetoclax Frequency: venetoclax tablets orally at dose of 400, 600 or 800 mg once daily (QD) continuously for 21 days. Drug: Rituximab Frequency: rituximab intravenously (IV) at dose of 375 mg/m² weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter. Experimental: Expansion Phase (Part 2) Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death. Drug: RO6870810 Frequency: RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles. Drug: Venetoclax Frequency: venetoclax tablets orally at a dose of 400, 600 or 800 mg once daily (QD) continuously for 21 days. Drug: Rituximab Frequency: rituximab intravenously (IV) at dose of 375 mg/m² weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | RO6870810, venetoclax, rituximab |
| Primary outcome measure | 1. Percentage of Participants With Dose-Limiting Toxiciities (DLT)- Part 1 [ Time Frame: Cycle (C) 1 (21 days) ] DLT is defined as any of the toxicities- occurs within the first cycle for which the participant receives the full intended combination doses and number of administrations; is considered to be related to study treatment by the investigator; is not attributed to disease progression or another clearly identifiable cause. 2. Percentage of Participants With Adverse Events (AEs) - Part 1 [ Time Frame: Up to 36 months ] An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 3. Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 1 [ Time Frame: Up to 36 months ] 4. Complete Response (CR) Rate as Determined by Independent Radiological Central Review (ICR) Using Modified Lugano Response Criteria- Recommended Dose (RD) Expansion - Part 2 [ Time Frame: Up to 36 months ] 5. Overall Response (OR) Rate as Determined by Independent Radiological Central Review (ICR) Using Modified Lugano Response Criteria- RD Expansion - Part 2 [ Time Frame: Up to 36 months ] |
| Secondary outcome measures | 1. Percentage of Participants With Adverse Events (AEs) - Part 2 [ Time Frame: Up to 36 months ] An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 3. Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 2 [ Time Frame: Up to 36 months ] 4. Maximum Concentration (Cmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2 [ Time Frame: Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months) ] 5. Trough Serum Concentration (Cmin) of RO6870810 and its Potential Metabolites- Part 1 and Part 2 [ Time Frame: Pre-dose Cycle 2 and all other subsequent even Cycles (Up to 36 months) ] 6. Time of Maximum Concentration (tmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2 [ Time Frame: Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months) ] 7. Clearance (CL) of RO6870810 and its Potential Metabolites- Part 1 and Part 2 [ Time Frame: Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months) ] 8. Volume of Distribution (Vd) of RO6870810 and its Potential Metabolites- Part 1 and Part 2 [ Time Frame: Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months) ] 9. Area Under the Curve (AUC) of RO6870810 and its Potential Metabolites- Part 1 and Part 2 [ Time Frame: Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months) ] 10. Complete Response (CR) Rate as Determined by the Investigator Based on the Modified Lugano Response Criteria- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 11. Complete Response (CR) Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 12. Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of Modified Lugano Response Criteria- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 13. Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 14. Duration of Response (DoR)- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 15. Progression-Free Survival (PFS)- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 16. Event-Free Survival (EFS)- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 17. Disease-Free Survival (DFS)- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 18. Overall Survival (OS)- Part 1 and Part 2 [ Time Frame: Up to 36 months ] 19. Half-Life (t1/2) of RO6870810 and its Potential Metabolites- Part 1 and Part 2 [ Time Frame: Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months) ] 20. Percentage of Ant-Drug Antibodies (ADA) Against Rituximab - Part 1 and Part 2 [ Time Frame: Pre-dose, End of Infusion Day 1 Cycle 1; Pre-dose Day 1 Cycle 2, 3, 4 , 6 and all other even Cycles (Up to 36 months) ] |
| Overall study start date | 01/12/2016 |
| Overall study end date | 03/07/2019 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Mixed |
| Sex | Both |
| Target number of participants | 39 |
| Total final enrolment | 39 |
| Participant inclusion criteria | 1. Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. 2. Life expectancy >3 months as per investigator's assessment. Part 1 and Part 2 Group 1: 3. Participants with diffuse large B-cell lymphoma (DLBCL) relapsed or refractory to ≥1 course of chemotherapy including an anti-CD20 monoclonal antibody, and not eligible for autologous stem cell transplantation (ASCT) (including due to chemorefractory disease). Participants with transformed FL are eligible, provided DLBCL or HGBL-DH/TH histology is biopsy-confirmed prior to study entry and a treatment regimen as described above has been administered. The Sponsor retains the option to limit the number of participants enrolled with transformed FL. Part 2, Group 2: 4. Patients identified with DE-DLBCL (expression MYC ≥40%, BCL2 >50%) and or HGBL-DH/TH, relapsed or refractory to >=1 course of chemotherapy including an anti-CD20 monoclonal antibody, and not eligible for ASCT (including due to chemorefractory disease). Patients with transformed follicular lymphoma (FL) are eligible, provided DE-DLBCL and/or HGBL-DH/TH histology is biopsy-confirmed prior to study entry and a treatment regimen as described above has been administered. The Sponsor retains the option to limit the number of participants enrolled with transformed FL. Part 1 and Part 2: 5. Willing to provide the protocol specified tumor biopsy(ies): at screening a fresh biopsy (if no archival biopsy tissue of less than 3 months prior to treatment and without intercurrent treatment is available); Part 2: 6. Willing to provide an additional biopsy on Cycle 2 Day 15 (+2 days). 7. Acceptable liver function, as specified below: 7.1. Total bilirubin ≤2 times upper limit of normal (ULN). (Participants with known Gilbert's disease who has serum bilirubin ≤3 × ULN may be enrolled) 7.2. Aspartate transaminase (AST; SGOT), alanine transaminase (ALT; SGPT) ≤2.5 × ULN, (or ≤5 × ULN if tumor involvement (liver) is present) 7.3. Gamma-glutamyl transferase (GGT) alkaline phosphatase ≤2.5 × ULN 8. Acceptable renal function, as specified below: 8.1. Creatinine clearance (CrCl) calculated by Cockroft-Gault formula of ≥60 mL/min 9. Acceptable hematologic status (growth factors cannot be used within the previous 7 days), as specified below: 9.1. Absolute neutrophil count (ANC) ≥1000 cells/μL 9.2. Hemoglobin ≥9 g/dL 9.3. Platelet count ≥75,000 (platelets/μL) 9.4. Uncontrolled symptomatic hypercalcemia 10. Acceptable coagulation status, as specified below: 10.1. Prothrombin time (PT) and partial thromboplastin time (PTT) ≤1.2 × ULN (unless receiving anticoagulation therapy, if receiving anticoagulation therapy, eligibility will be based upon international normalized ratio [INR]) 10.2. INR ≤1.6 (unless receiving anticoagulation therapy) 10.3. If receiving warfarin: INR ≤3.0 and no active bleeding (i.e., no bleeding within 14 days prior to first dose of study therapy). 11. Acceptable method of contraception |
| Participant exclusion criteria | 1. Current central nervous system (CNS) lymphoma or leptomeningeal infiltration 2. New York Heart Association (NYHA) Class III or IV cardiac disease, myocardial infarction, within the past 6 months, unstable arrhythmia, or known pericardial disease 3. Fredericia-corrected QT interval (QTcF) >470 msec (female) or >450 msec (male), or history of congenital long QT syndrome 4. Any electrocardiogram (ECG) abnormality, which in the opinion of the Investigator would preclude safe participation in the study 5. Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy 6. Clinically important respiratory impairment 7. Grade ≥3 sensory or motor neuropathy 8. Any Grade >1 (according to the NCI CTCAE 4.03) adverse reaction unresolved from previous treatments and not readily managed and controlled with supportive care 9. Serious non-malignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor 10. History of progressive multifocal leukoencephalopathy (PML) 11. History of other malignancy within 2 years prior to screening, except for ductal carcinoma in situ not requiring chemotherapy, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, low-grade, localized prostate cancer (Gleason score ≤7) not requiring treatment or appropriately treated Stage I uterine cancer 12. Completion of ASCT within 100 days prior to Day 1 of Cycle1 13. Prior standard or investigational anti-cancer therapy, as specified below: 13.1. Radio-immunoconjugate 4 weeks or 5 half-lives, whichever is longer prior to Day 1 of Cycle 1 13.2. Monoclonal antibody or antibody-drug conjugate (ADC) therapy within 3 weeks prior to Day 1 of Cycle 1 13.3. Radiotherapy, chemotherapy, or targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1 13.4. CAR T-cell therapy 30 days prior to Day 1 of Cycle 1 14. History of major solid organ transplant (i.e., heart, lungs, liver and kidney) 15. History of an allogeneic bone marrow transplant 16. Major surgical procedure within 28 days prior to Day 1 of Cycle 1 17. Treatment with systemic corticosteroids ≥20 mg/day prednisone or equivalent, for non-lymphoma treatment reasons. For lower acceptable doses, documentation of a stable dose for at least 4 weeks prior to Day 1 of Cycle 1 is required 18. Treatment with strong to moderate CYP3A inhibitors or moderate CYP3A inducers within 7 days prior to the first dose of study treatment 19. Treatment with strong CYP3A inducers within 14 days prior to the first dose of study treatment of RO6870810/venetoclax 20. Consumption of grapefruits, grapefruit products, Seville oranges (including marmalade that contains Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax 21. Participants who are currently receiving any other investigational agent ((other than anti-cancer therapy as specified in exclusion criteria number 13) or have received an investigational agent within 30 days or 5 half-lives prior to Day 1 of Cycle 1, whichever is longer 22. Prior treatment with small molecule bromodomain and extra terminal (BET) family inhibitor 23. Known to be human immunodeficiency virus (HIV) positive 24. Presence of positive test results for hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HcAb) (for participants receiving regimen including rituximab) 25. Pregnant or breastfeeding female 26. Significant allergy to a biological pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the participant 27. Uncontrolled cancer pain. Participants requiring pain medication must be on a stable regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy should be treated prior to enrollment 28. History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies (for participants receiving regimen including rituximab) 29. Known sensitivity or allergy to murine products or any component of RO6870810, venetoclax, or rituximab |
| Recruitment start date | 28/08/2017 |
| Recruitment end date | 12/03/2019 |
Locations
Countries of recruitment
- Australia
- Denmark
- Spain
- United States of America
Study participating centres
91010
United States of America
94305-5820
United States of America
10065
United States of America
28203
United States of America
3000
Australia
København
2100
Denmark
Barcelona
08025
Spain
Barcelona
08907
Spain
Madrid
28040
Spain
Sponsor information
Industry
1 DNA Way
San Francisco
94080
United States of America
| Phone | +1 888-662-6728 |
|---|---|
| global-roche-genentech-trials@gene.com | |
| Website | www.roche.com/about_roche/roche_worldwide.htm |
Funders
Funder type
Industry
Private sector organisation / For-profit companies (industry)
- Alternative name(s)
- Genentech, Inc., Genentech USA, Inc., Genentech USA
- Location
- United States of America
Results and Publications
| Intention to publish date | 01/04/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not expected to be made available |
| Publication and dissemination plan | Planned publication in a peer-reviewed journal. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available due to participant-level data not being a regulatory requirement |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 23/11/2021 | 15/03/2022 | Yes | No |
Editorial Notes
16/03/2022: IPD sharing statement added.
15/03/2022: Publication reference added.
02/02/2021: Removed bad link in participant information sheet field.
17/11/2020: Trial’s existence confirmed by Western Institutional Review Board.
